Comparative Pharmacology
Head-to-head clinical analysis: CHILDREN S CLARITIN versus CLARITIN D.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHILDREN S CLARITIN versus CLARITIN D.
CHILDREN'S CLARITIN vs CLARITIN-D
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Loratadine is a long-acting second-generation antihistamine that selectively antagonizes peripheral histamine H1 receptors, thereby inhibiting the effects of histamine released from mast cells and basophils, reducing allergic symptoms.
Loratadine is a long-acting tricyclic antihistamine with selective peripheral H1 receptor antagonism. Pseudoephedrine is a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction.
10 mg orally once daily
One tablet (5 mg loratadine/120 mg pseudoephedrine sulfate) orally every 12 hours; do not exceed 2 tablets in 24 hours.
None Documented
None Documented
The terminal elimination half-life of loratadine is 8-14 hours (mean 11 hours) in healthy adults; for the active metabolite descarboethoxyloratadine, half-life is 17-24 hours (mean 20 hours). This supports once-daily dosing.
Loratadine: 8-14 h (mean 11 h); desloratadine: 17-24 h (mean 21 h). Pseudoephedrine: 4-8 h (mean 6 h), prolonged in alkaline urine.
Loratadine is primarily eliminated via hepatic metabolism, with approximately 80% of the dose excreted as metabolites in urine (40%) and feces (40%). Less than 1% is excreted unchanged in urine.
Loratadine: 40% renal (metabolites), ~40% fecal; desloratadine: 33% renal, 66% fecal. Pseudoephedrine: 70-90% renal unchanged, 1-2% biliary.
Category C
Category C
Antihistamine
Antihistamine/Decongestant Combination